SCHEMBL2406706

SCHEMBL2406706

OB(c1ccc(C(F)(F)F)cc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV6 Q9H1D0 5/20 1.00
ORAI1 Q96D31 4/20 1.00
ORAI2 Q96SN7 4/20 1.00
ORAI3 Q9BRQ5 4/20 1.00
MGLL Q99685 2/20 0.73
KIF11 P52732 4/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
PCSK9 Q8NBP7 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
EPHX2 P34913 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
PLAU P00749 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3275158 0.91 TRPV6 (1.00) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL12270441 0.89 TRPV6 (0.79) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL3274513 0.87 TRPV6 (0.76) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL2406670 0.87 TRPV6 (0.76) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL4179 0.84 MGLL (1.00) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL16653473 0.83 TRPV6 (0.71) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL2399721 0.82 TRPV6 (0.68) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL12266260 0.81 TRPV6 (0.69) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL14477120 0.80 TRPV6 (0.67) TRPV6ORAI1ORAI2ORAI3MGLL
SCHEMBL12266256 0.78 MAOB (0.64) TRPV6ORAI1ORAI2ORAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6600066-B1 Process for preparing perhalogenated monoorganoboranes or diorganoboranes which makes it possible to obtain these compounds under conditions which can readily be implemented in the industry is described. BASELL POLYOLEFINE GMBH (DE) 2003-07-29 US claimed
US-20260050210-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING SAME NIPPON SHOKUBAI CO., LTD. (JP) 2026-02-19 US disclosed
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 US disclosed
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 US disclosed
WO-2010018837-A2 PROTEIN CROSS-LINKING INHIBITOR 独立行政法人科学技術振興機構 (JP) 2010-02-18 WO disclosed
WO-2010018836-A2 POLYGLUTAMINE AGGREGATION INHIBITOR 独立行政法人科学技術振興機構 (JP) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR BAZ2B, PRMT1, BRIX1 TRPV6 4868/4885ORAI1 4605/4885ORAI2 3906/4885
US-20260050210-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING SAME MAL2, MCM6, MCM3 TRPV6 2089/4885ORAI1 505/4885ORAI2 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.